Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Gilbert

Showing results (291-300 of 453) with videos related to

Pageof 46
Sort By:
Neuro-Oncology|July 6, 2019
Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastomaJing Cui, Qi Zhang, Qi Song, et al.
Neuro-Oncology Practice|June 9, 2025
Implications of sociodemographic and clinical factors on symptom burden: Age-specific survivorship care in the primary central nervous system tumor populationKimberly R Robins, Tricia Kunst, Jennifer Reyes, et al.
Neuro-Oncology Advances|October 2, 2023
The sex-dependent impact of PER2 polymorphism on sleep and activity in a novel mouse model of cranial-irradiation-induced hypersomnolenceKendra A Adegbesan, Francesco Tomassoni Ardori, Sudhirkumar Yanpallewar, et al.
Frontiers in Oncology|August 2, 2021
Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS MalignanciesNivedita M Ratnam, Heather M Sonnemann, Stephen C Frederico, et al.
Neuro-Oncology Advances|January 31, 2024
TGF-β and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcomaAiguo Li, John C Hancock, Martha Quezado, et al.
Neuro-Oncology Advances|July 10, 2020
NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop ProceedingsBrett J Theeler, Yamini Dalal, Michelle Monje, et al.
Neuro-Oncology|August 30, 2024
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomasFelix Sahm, Kenneth D Aldape, Priscilla K Brastianos, et al.
Cancer|November 17, 2011
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic gliomaPierre Giglio, Megha Dhamne, Kenneth R Hess, et al.
Frontiers in Oncology|August 19, 2022
Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in <i>PMS2</i>Mythili Merchant, Margarita Raygada, Ying Pang, et al.
Journal of Neuro-Oncology|July 14, 2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaShiao-Pei Weathers, Xiaosi Han, Diane D Liu, et al.
Pageof 46

Showing results (291-300 of 453) with videos related to

Sort By:
Pageof 46
Neuro-Oncology|July 6, 2019
Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastomaJing Cui, Qi Zhang, Qi Song, et al.
Neuro-Oncology Practice|June 9, 2025
Implications of sociodemographic and clinical factors on symptom burden: Age-specific survivorship care in the primary central nervous system tumor populationKimberly R Robins, Tricia Kunst, Jennifer Reyes, et al.
Neuro-Oncology Advances|October 2, 2023
The sex-dependent impact of PER2 polymorphism on sleep and activity in a novel mouse model of cranial-irradiation-induced hypersomnolenceKendra A Adegbesan, Francesco Tomassoni Ardori, Sudhirkumar Yanpallewar, et al.
Frontiers in Oncology|August 2, 2021
Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS MalignanciesNivedita M Ratnam, Heather M Sonnemann, Stephen C Frederico, et al.
Neuro-Oncology Advances|January 31, 2024
TGF-β and BMP signaling are associated with the transformation of glioblastoma to gliosarcoma and then osteosarcomaAiguo Li, John C Hancock, Martha Quezado, et al.
Neuro-Oncology Advances|July 10, 2020
NCI-CONNECT: Comprehensive Oncology Network Evaluating Rare CNS Tumors-Histone Mutated Midline Glioma Workshop ProceedingsBrett J Theeler, Yamini Dalal, Michelle Monje, et al.
Neuro-Oncology|August 30, 2024
cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomasFelix Sahm, Kenneth D Aldape, Priscilla K Brastianos, et al.
Cancer|November 17, 2011
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic gliomaPierre Giglio, Megha Dhamne, Kenneth R Hess, et al.
Frontiers in Oncology|August 19, 2022
Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in <i>PMS2</i>Mythili Merchant, Margarita Raygada, Ying Pang, et al.
Journal of Neuro-Oncology|July 14, 2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaShiao-Pei Weathers, Xiaosi Han, Diane D Liu, et al.
Pageof 46